Molecular Findings Before Vision Loss in the Streptozotocin-Induced Rat Model of Diabetic Retinopathy

Mădălina Moldovan1, Roxana-Denisa Capraș1, Raluca Paşcalău2,3

  • 1Department of Anatomy and Embryology, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.

PubMed

Insights

Diabetic retinopathy progresses rapidly within four weeks of hyperglycemia, causing vision loss. This review details weekly changes in the streptozotocin-induced rat model, highlighting vascular damage and neovascularization as key factors.

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Pathology

Background:

  • Diabetic retinopathy (DR) is a leading cause of vision loss.
  • The streptozotocin-induced (STZ) rat model mimics human DR progression.
  • Understanding early DR pathogenesis is crucial for timely intervention.

Purpose of the Study:

  • To provide a chronological, week-by-week review of DR progression in the STZ rat model.
  • To detail the pathological changes occurring in the initial four weeks of hyperglycemia.
  • To establish a framework for understanding early DR development.

Main Methods:

  • Review of existing literature on the STZ-induced rat model of diabetic retinopathy.
  • Chronological data structuring based on weekly intervals post-diabetes induction.
  • Focus on key pathological events including vascular damage, inflammation, and neuronal changes.

Main Results:

  • Week 1: Oxidative stress activates retinal microglia, causing inflammation and altered neurotransmission.
  • Week 2: Leukostasis promotes ischemia; neural degeneration and increased vessel permeability begin.
  • Week 3: Worsening redox and inflammatory imbalances.
  • Week 4: Vessel dilation, tortuosity, neovascularization, retinal thinning, and vision loss occur.

Conclusions:

  • The STZ rat model exhibits a rapid, four-week progression of DR mirroring human disease.
  • Early stages involve oxidative stress, inflammation, and vascular changes.
  • Vascular damage and neovascularization are critical drivers of vision loss in this model.